• Medical - Devices
  • Healthcare
Edwards Lifesciences Corporation logo
Edwards Lifesciences Corporation
EW · US · NYSE
62.37
USD
+2.67
(4.28%)
Company Overview

ONE EDWARDS WAY,IRVINE CA 92614,9492502500

CEO

Mr. Bernard J. Zovighian

Employess

19800

Sector

Healthcare

Industry

Medical - Devices

Website

https://www.edwards.com

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Next Earnings Date

Oct. 23, 2024

Ex Dividends date

--

Dividend Date

--

YTD Performance

-17.47%

Fiscal Year End

12-31

IPO Date

2000-03-27

Growth Rates
(avg. rate of change) 10 years 5 years 3 years 1 year
Sales/Revenue 11.37% 10.03% 11.04% 11.56%
EPS 14.62% 14.97% 20.51% -6.10%
Equity 15.61% 16.19% 13.28% 14.52%
Cash 10.53% 9.88% -1.12% 48.76%
Return On Capital (ROIC) 18.94% 21.76% 19.90% 18.29%
Debt
year (millions) 2023 2022 2021 2020 2019
Short Term Debt 24.9 25.5 25.5 27.2 25.5
Long Term Debt 670 666 665 668 653
LT Finance Leases 97.9 95 94.6 99.9 84.4
Shares Outstanding 607 619 623 623 625
Market Cap 46,300 46,200 80,700 56,800 48,600
Price
Business Segments (Beta)
Geographical Segments (Beta)
News
An Investigation Has Commenced on Behalf of Edwards Lifesciences Corporation Shareholders. Contact Levi & Korsinsky to Discuss your EW Losses.
2 months

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.

accesswire.com
3 Healthcare Stocks to Buy at a 52-Week Low in July
2 months

Finding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.

investorplace.com
Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
2 months

Edwards Lifesciences cut TAVR guidance, stock price dropped by over 31%. Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market. Analyst reiterates 'Strong Buy' rating with a fair value of $72 per share, confident in long-term growth potential.

seekingalpha.com
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Edwards Lifesciences Corporation (EW)
2 months

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.

accesswire.com
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product
2 months

Major U.S. equities indexes were mixed after a report showing U.S. gross domestic product (GDP) grew at a greater-than-expected annualized rate of 2.8% in the second quarter.

investopedia.com
Edwards Lifesciences Stock Plummeted Today. Here's Why
2 months

Edwards Lifesciences (EW) shares swooned Thursday, dropping after the company damped expectations for heart valve replacement sales growth on Wednesday.

investopedia.com
Edwards Lifesciences Stock Tumbles, Highlights Slowdown In TAVR Business
2 months

Edwards Lifesciences Corp EW reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents.

benzinga.com
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
2 months

Edwards Lifesciences Corporation EW reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.

benzinga.com
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
2 months

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

zacks.com
Why Is Edwards Lifesciences (EW) Stock Down 22% Today?
2 months

Edwards Lifesciences (NYSE: EW ) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents.

investorplace.com
Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences
2 months

Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China , July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, today commented on the expected acquisition of JenaValve Technology, Inc. ("JenaValve"), an exclusive technology licensing partner of Peijia, by Edwards Lifesciences ("Edwards"). On July 24, 2024, Edwards announced that it had entered into an agreement to acquire JenaValve, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is currently untreated today.

prnewswire.com
Edwards Lifesciences Stock Plunges 24% After Earnings. What Wall Street Thinks.
2 months

The medical-technologies company misses second-quarter sales estimates.

barrons.com